SOUTH SAN FRANCISCO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Greg Chow as Chief Financial Officer (CFO), effective June 2, 2025. Mr. Chow brings over 25 years of executive leadership experience across corporate finance, capital markets, investment banking, financial accounting, and drug development operations. “We are ...